Organization
Kinghorn Cancer Centre
2 abstracts
Abstract
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).Org: King's College London, Imperial College, University College London Cancer Institute, University College London Hospital NHS Trust and Great Ormond Street Hospital, Kinghorn Cancer Centre,
Abstract
Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.Org: Garvan Institute of Medical Research, Sydney, Australia, Kinghorn Cancer Centre, Darlinghurst, Australia,